Abstract
Objective
99mTc-tetrofosmin and99mTc-sestamibi are approved tracers for myocardial perfusion studies. Recently, a99mTc-MIBI preparation from a different manufacturer (99mTc-cardiospect-MIBI) has been introduced to the market. Therefore, the aim of this study was the evaluation of99mTc-tetrofosmin as well as of two different99mTc-labeled MIBI tracers with regard to differences in imaging quality under resting conditions.
Methods
Sixty patients (mean age 63.8 years ± 1.25) with known or suspected coronary artery disease but without evidence of rest-ischemia were included. Twenty patients in each group were examined by a two-day-rest-stress protocol using the three99mTc-labeled tracers. Visual analysis of all images was performed by two experienced physicians blinded with regard to the applied tracer. Regions of interest (ROI) were defined over the heart, lung and whole body only in the rest imaging in order to calculate heart-to-lung, lung-to-whole body-, and heart-to-whole body-ratios.
Results
The heart-to-lung ratio was statistically significant higher for99mTc-cardiospect-MIBI as compared to99mTc-sestamibi as well as to99mTc-tetrofosmin. Furthermore, a significantly higher heart-to-lung ratio was found for99mTc-sestamibi as compared to99mTc-tetrofosmin. The heart-to-whole body-ratio and the lung-to-whole body-ratio were equivalent between all tracers. Visual analysis revealed only slight differences regarding image quality between all tracers.
Conclusions
ROI analysis surprisingly revealed a significant higher myocardial uptake and consequently a higher heart-to-lung ratio for99mTc-cardiospect-MIBI. Whether this leads to a better visual image quality has to be evaluated in future studies with larger study populations as well as semiquantitative segmental analysis of the myocardial perfusion images.
Similar content being viewed by others
references
Hurwitz G A, Ghali SK, Husni M, et al. Pulmonary uptake of technetium-99m-sestamibi induced by dipyridamole-based stress or exercise.J Nucl Med 1998; 39: 339–345.
Sridhara BS, Braat S, Rigo P, Itti R, Cload P, Lahiri A. Comparison of myocardial perfusion imaging with techne-tium-99m tetrofosmin versus thallium-201 in coronary artery disease.Am J Cardiol 1993; 72: 1015–1019.
Acampa W, Cuocolo A, Sullo P, et al. Direct comparison of technetium 99m-sestamibi and technetium 99m-tetrofosmin cardiac single photon emission computed tomography in patients with coronary artery disease.J Nucl Cardiol 1998; 3: 265–274.
Münch G, Neverve J, Matsunari I, Schröter G, Schwaiger M. Myocardial technetium-99m-tetrofosmin and technetium-99m-sestamibi kinetics in normal subjects and patients with coronary artery disease.J Nucl Med 1997; 38: 428–432.
Soman P, Taillefer R, DePuey EG, Undelson JE, Lahiri A. Enhanced detection of reversible perfusion defects by Tc- 99m-sestamibi during vasodilator stress SPECT imaging in mild-to-moderate coronary artery disease.J Am Coll Cardiol 2001;37:458–462.
Kapur A, Latus KA, Davies G, et al. A comparison of three radionuclide myocardial perfusion tracers in clinical practice: the ROBUST study.Eur J Nucl Med 2002; 29: 1608–1616.
Arbab AS, Koizumi K, Toyama K, Arai T, Araki T. Technetium-99m-Tetrofosmin, Technetium-99m-MIBI and Thallium-201 uptake in rat myocardial cells.J Nucl Med 1998;39:266–271.
Flamen P, Bossuyt A, Franken PR. Technetium-99m-Tetrofosmin in dipyridamole-stress myocardial SPECT imaging: intraindividual comparison with technetium-99m-sestamibi.J Nucl Med 1995; 36: 2009–2015.
Iskander S, Iskander AE. Risk assessment using single-photon emission computed tomographic technetium-99m sestamibi imaging.J Am Coll Cardiol 1998; 32: 57–62.
Schuijf JD, Shaw LJ, Wijns W, et al. Cardiac imaging in coronary artery disease: differing modalities.Heart 2005; 91: 1110–1117.
Caner B, Beller GA. Are technetium-99m-labeled myocardial perfusion agents adequate for detection of myocardial viability?Clin Cardiol 1998; 21: 235–242.
Bangard M, Bender H, Grünwald F, et al. Myocardial uptake of Technetium-99m-Furifosmin (Q12) versus Technetium-99m-Sestamibi (MIBI).Nuklearmedizin 1999; 38: 189–191.
Jain D. Technetium99m labelled myocardial perfusion imaging agents.Semin Nucl Med 1999; 29: 221–236.
Wackers FJ, Berman DS, Maddahi J, et al. Technetium-99m hexakis 2-ethoxyisobutyl isonitrile: human biodistribution, dosimetry, safety and preliminary comparison to thallium-201 for myocardial perfusion imaging.J Nucl Med 1989; 30: 301–311.
Jain D, Zaret BL. Technetium 99m Tetrofosmin. In: Iskandrian AE, Verani MS, eds.New developments in cardiac nuclear imaging. Armonk, NY; Futura Publishing, 1998: 29–58.
Maisey MN, Mistry R, Sowton E. Planar imaging techniques used with technetium-99m-sestamibi kinetics to evaluate chronic myocardial ischemia.Am J Cardiol 1990; 66: 47E-54E.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Manka-Waluch, A., Palmedo, H., Reinhardt, M.J. et al. Myocardial uptake characteristics of three99mTc-labeled tracers for myocardial perfusion imaging one hour after rest injection. Ann Nucl Med 20, 663–670 (2006). https://doi.org/10.1007/BF02984677
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02984677